ICAM1 and neoplasm: In our experimental model, since systemic ICAM-1 blockade did not prevent the access of tumor egressing CD8+ T lymphocytes to the lymphatic vessels, we assume that their transit is integrin independent and would probably occur through small portals that due to small size would not fit cell aggregates of more than 2-3 T-cells (42).